Genetesis, a Mason startup that’s developing medical devices to detect heart disease and is considering an initial public offering of stock, has hired a former Assurex Health executive as chief business officer.
Peter Donato was chief financial officer for Mason-based Assurex Health from 2015 to 2017, but the company has rebranded as Myriad Neuroscience since being bought by Myriad Genetics of Salt Lake City in a deal worth at least $225 million. Donato played a key role in the Assurex deal, which could be worth up to $410 million if milestones are hit.
Click here to read the complete article.
Story excerpt provided by Cincinnati Business Courier.
Written by Barrett J. Brunsman.
Originally published August 27, 2019.